Browsing by Author "Limotai, Natlada"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Open Access Deep brain stimulation for tremor associated with underlying ataxia syndromes: a case series and discussion of issues.(Tremor Other Hyperkinet Mov (N Y), 2014) Oyama, Genko; Thompson, Amanda; Foote, Kelly D; Limotai, Natlada; Abd-El-Barr, Muhammad; Maling, Nicholas; Malaty, Irene A; Rodriguez, Ramon L; Subramony, Sankarasubramoney H; Ashizawa, Tetsuo; Okun, Michael SBACKGROUND: Deep brain stimulation (DBS) has been utilized to treat various symptoms in patients suffering from movement disorders such as Parkinson's disease, dystonia, and essential tremor. Though ataxia syndromes have not been formally or frequently addressed with DBS, there are patients with ataxia and associated medication refractory tremor or dystonia who may potentially benefit from therapy. METHODS: A retrospective database review was performed, searching for cases of ataxia where tremor and/or dystonia were addressed by utilizing DBS at the University of Florida Center for Movement Disorders and Neurorestoration between 2008 and 2011. Five patients were found who had DBS implantation to address either medication refractory tremor or dystonia. The patient's underlying diagnoses included spinocerebellar ataxia type 2 (SCA2), fragile X associated tremor ataxia syndrome (FXTAS), a case of idiopathic ataxia (ataxia not otherwise specified [NOS]), spinocerebellar ataxia type 17 (SCA17), and a senataxin mutation (SETX). RESULTS: DBS improved medication refractory tremor in the SCA2 and the ataxia NOS patients. The outcome for the FXTAS patient was poor. DBS improved dystonia in the SCA17 and SETX patients, although dystonia did not improve in the lower extremities of the SCA17 patient. All patients reported a transient gait dysfunction postoperatively, and there were no reports of improvement in ataxia-related symptoms. DISCUSSION: DBS may be an option to treat tremor, inclusive of dystonic tremor in patients with underlying ataxia; however, gait and other symptoms may possibly be worsened.Item Open Access Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale.(Journal of movement disorders, 2022-03-16) Jagota, Priya; Srivanitchapoom, Prachaya; Petchrutchatachart, Sitthi; Singmaneesakulchai, Surat; Pisarnpong, Apichart; Lolekha, Praween; Setthawatcharawanich, Suwanna; Chairangsaris, Parnsiri; Limotai, Natlada; Mekawichai, Pawut; Panyakaew, Pattamon; Phokaewvarangkul, Onanong; Sringean, Jirada; Pitakpatapee, Yuvadee; LaPelle, Nancy; Martinez-Martin, Pablo; Ren, Xuehan; Luo, Sheng; Stebbins, Glenn T; Goetz, Christopher G; Bhidayasiri, RoongrojObjective
This study aims to validate the Thai translation of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS).Methods
The English version was translated into Thai and then back-translated into English. The translated version underwent 2 rounds of cognitive pretesting to assess the ease of comprehension, ease of use and comfort with the scale. Then, it underwent large clinimetric testing.Results
The Thai version was validated in 354 PD patients. The comparative fit index (CFI) for all four parts of the Thai version of the MDS-UPDRS was 0.93 or greater. Exploratory factor analysis identified isolated item differences in factor structure between the Thai and English versions.Conclusion
The overall factor structure of the Thai version was consistent with that of the English version based on the high CFIs (all CFI ≥ 0.90). Hence, it can be designated the official Thai version of the MDS-UPDRS.